WHO Prequalified Drugs with Limited African Market Registration — Africa Market Entry Intelligence 2026
Discover 30 WHO-prequalified medicines with fewer than 3 active registrations in African markets, highlighting significant market access gaps and patient needs.
A recent analysis by AfriReg reveals that 30 WHO-prequalified medicines currently have fewer than three active registrations across tracked African markets. This significant finding underscores substantial market access gaps and represents critical opportunities for pharmaceutical manufacturers to expand their reach while addressing unmet patient needs across the continent.
The World Health Organization (WHO) prequalification program is a global initiative ensuring the quality, safety, and efficacy of essential medicines, particularly for low- and middle-income countries. Products that receive WHO prequalification have undergone rigorous assessment, making them suitable for procurement by UN agencies and a benchmark for national regulatory authorities. Despite this stamp of approval, many of these vital medicines struggle to achieve widespread registration and market penetration in African nations.
Understanding the Market Access Gap
The data highlights a paradoxical situation: medicines deemed essential and quality-assured by the WHO are not consistently reaching patients in African markets. This limited registration points to several challenges and, crucially, significant opportunities. For manufacturers, these 30 products represent an untapped market where their prequalified status can be a compelling advantage for market entry.
For patients, the lack of availability of these medicines translates to continued suffering from preventable or treatable conditions. Many of the listed drugs are critical for combating diseases prevalent in Africa, such as HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases.
Key Observations from the Data
Our analysis of the 30 products with limited registration reveals several patterns:
- Anti-infectives Dominate: A significant portion of the medications are anti-infectives, including antiretrovirals (ARVs) like various combinations of Abacavir, Dolutegravir, Lamivudine, Tenofovir, and Efavirenz. This indicates persistent challenges in establishing broad access to HIV/AIDS treatments despite global efforts.
- Specialized Formulations: Several products are specialized formulations, such as 'Tablets for Oral Suspension' (e.g., Abacavir, Dolutegravir and Lamivudine Tablets for Oral) or 'Granules for Oral suspension' (e.g., Artesunate/Pyronaridine), which are often critical for paediatric populations or patients with swallowing difficulties. Limited registration of these specific formulations points to an unmet need for age-appropriate medicines.
- Novel or Complex Drugs: Products like Dapivirine Vaginal ring, Fexinidazole (for sleeping sickness), and Cefiderocol (a novel antibiotic) indicate challenges beyond typical market entry. These may require more targeted regulatory outreach, specific national guidelines, or heightened awareness campaigns for prescribers and patients.
- Diverse Manufacturers: The list includes products from a wide range of manufacturers, from large Indian generics players like Emcure, Mylan, and Aurobindo, to specialized firms like International Partnership for Microbicides (IPM Belgium) and even Japanese innovator Shionogi. This diversity suggests the market access issue is not confined to a specific type of manufacturer but rather indicative of broader systemic challenges in African market penetration.
The Opportunity: Addressing Unmet Needs and Expanding Market Share
For pharmaceutical companies, these 30 prequalified products represent a clear strategic opportunity. By proactively pursuing registrations in additional African markets, manufacturers can:
- Leverage WHO Prequalification: The WHO prequalification status significantly streamlines the registration process in many African countries, often serving as an abbreviated pathway or providing a strong basis for national regulatory approval.
- Drive Social Impact: Addressing critical health needs in underserved populations aligns with corporate social responsibility goals and can enhance brand reputation.
- Secure First-Mover Advantage: For many of these products, particularly specialized ones, expanding registration could establish a manufacturer as a key supplier in new territories.
- Expand Commercial Footprint: Increased registrations lead to greater market access, sales volumes, and diversification of revenue streams across a continent experiencing significant population growth and increasing healthcare investment.
Regulators and public health bodies in Africa can also draw insights from this data, identifying critical medicines whose availability should be prioritized through accelerated registration pathways or targeted procurement initiatives.
Detailed Data: WHO Prequalified Medicines with Limited African Registration
The following table lists the 30 WHO-prequalified medicines identified with fewer than three active registrations in the African markets tracked by AfriReg:
| Product | Manufacturer | Form | Active Registrations |
|---|---|---|---|
| undefined (Abacavir (Sulfate), Dolutegravir (Sodium), and Lamivudine Tablets) | Emcure Pharmaceuticals Limited | Tablet | 1 markets |
| undefined (Abacavir (sulfate)/Lamivudine/Zidovudine) | Mylan Laboratories Ltd. | Tablet | 1 markets |
| undefined (Abacavir, Dolutegravir and Lamivudine Tablets for Oral) | Macleods Pharmaceuticals Ltd | Tablets for Oral Suspension | 1 markets |
| undefined (Amikacin (sulfate)) | Qilu Pharmaceutical Co.,Ltd | Solution for injection | 1 markets |
| undefined (Artesunate (sterile)) | Ipca Laboratories Ltd | 1 markets | |
| undefined (Artesunate/Pyronaridine (phosphate)) | Shin Poong Pharmaceutical Co Ltd | Tablet, Film-coated | 1 markets |
| undefined (Artesunate/Pyronaridine (phosphate) Granules for Oral) | Shin Poong Pharmaceutical Co Ltd | Granules for Oral suspension | 1 markets |
| undefined (Atazanavir (sulfate) Capsules, hard 200mg) | Laurus Labs Limited | Capsules, hard | 1 markets |
| undefined (Benzyl alcohol/Water for) | Biosimilar Collaborations Ireland Limited | Powder for concentrate for solution for infusion + Solvent for parenteral use | 1 markets |
| undefined (Cefiderocol) | Shionogi B.V. | Powder for concentrate for solution for infusion | 1 markets |
| undefined (Clofazimine Capsules, soft 100mg) | Dong-A ST Co., Ltd. | Capsules, soft | 1 markets |
| undefined (Cycloserine Capsules, hard 125mg) | Macleods Pharmaceuticals Ltd | Capsules, hard | 1 markets |
| undefined (Daclatasvir (dihydrochloride)/Sofosbuvir) | Mylan Laboratories Ltd. | Tablet, Film-coated | 1 markets |
| undefined (Dapivirine Vaginal ring 25mg) | International Partnership for Microbicides Belgium (IPM Belgium) AISBL | Vaginal ring | 1 markets |
| undefined (Darunavir (ethanolate)/Ritonavir) | Hetero Labs Ltd | Tablet, Film-coated | 1 markets |
| undefined (Diethylcarbamazine (citrate)) | Eisai Co Ltd | Tablet | 1 markets |
| undefined (Dolutegravir (Sodium), Lamivudine and Tenofovir Disoproxil Fumarate) | Emcure Pharmaceuticals Limited | Tablet | 1 markets |
| undefined (Dolutegravir (sodium)/Lamivudine null 50mg/300mg) | Emcure Pharmaceuticals Limited | 1 markets | |
| undefined (Dolutegravir (sodium)/Lamivudine/Tenofovir alafenamide) | Mylan Laboratories Ltd. | Tablet | 1 markets |
| undefined (Efavirenz Capsules, hard 100mg) | Aurobindo Pharma Ltd | Capsules, hard | 1 markets |
| undefined (Efavirenz Capsules, hard 200mg) | Aurobindo Pharma Ltd | Capsules, hard | 1 markets |
| undefined (Efavirenz Capsules, hard 50mg) | Aurobindo Pharma Ltd | Capsules, hard | 1 markets |
| undefined (Emtricitabine Capsules, hard 200mg) | Aurobindo Pharma Ltd | Capsules, hard | 1 markets |
| undefined (Ethambutol hydrochloride/Isoniazid) | Cadila Pharmaceuticals Ltd | Tablet, Film-coated | 1 markets |
| undefined (Etonogestrel Implant 68mg) | NV Organon | Implant | 1 markets |
| undefined (Fexinidazole) | Sanofi-aventis groupe | Tablet | 1 markets |
| undefined (Ganciclovir (sodium)) | Hainan Poly Pharma Co Ltd | Powder for solution for injection | 1 markets |
| undefined (Isoniazid/Rifampicin Capsules, hard 150mg/300mg) | Antibiotice SA | Capsules, hard | 1 markets |
| undefined (Itraconazole Capsules, hard 100mg) | Laboratorios Liconsa S.A. | Capsules, hard | 1 markets |
| undefined (Kanamycin (sulfate)) | Shanghai Harvest Pharmaceutical Co., Ltd | Solution for injection | 1 markets |
Conclusion
The significant number of WHO-prequalified medicines with limited market registration in Africa presents a dual challenge and opportunity. While it highlights persistent barriers to access for essential medicines, it also illuminates clear pathways for pharmaceutical manufacturers to expand their market presence and contribute meaningfully to public health outcomes. Strategic engagement with national regulatory authorities, understanding local market dynamics, and leveraging WHO prequalification will be crucial for companies aiming to bridge these gaps in 2026 and beyond.
AfriReg Pro automates the tracking of drug registrations, regulatory changes, and competitive landscapes across African markets, enabling regulatory and business development teams to identify such opportunities efficiently and launch market entry strategies with unparalleled precision.